Samsung Biologics’ spinoff sparks optimism over corporate value

Samsung Biologics has completed the spinoff off its biosimilar developing subsidiary Samsung Bioepis, with stocks of Samsung Biologics and Samsung Epis Holdings finishing their first trading session as separate companies on Monday. Analysts are revising up the estimated corporate value of the biopharmaceutical contract manufacturer, noting that its streamlined structure will be combined with lowered U.S. tariff risks to improve market sentiment on the company. Samsung Biologics closed at 1.789 million won on Monday, down 0.45 percent from Oct. 29, the last session before the stock was suspended from trading due to the spinoff. Despite separating its previously wholly owned subsidiary Samsung Bioepis, the market appears to believe that the company’s intrinsic value remains largely unchanged. In May, Samsung Biologics announced it would spin off a business division overseeing its subsidiary and new investments to create Samsung Epis Holdings. The new holding company would acquire the 100 percent stake in Bioepis from Biologics. With Samsung Epis Holdings debuting as an independent stockWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times